|
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
ADSTILADRIN® is the first and only FDA-approved intravesical gene therapy for patients with high-risk BCG-unresponsive NMIBC See Important Safety Info
- Nadofaragene firadenovec - Wikipedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
- Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
- Nadofaragene firadenovec-vncg (urinary bladder route)
Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
- Mechanism of action of nadofaragene firadenovec-vncg - PMC
Effective bladder-preserving therapeutic options are needed for patients with bacillus Calmette-Guérin unresponsive non–muscle-invasive bladder cancer Nadofaragene firadenovec-vncg (Adstiladrin®) was approved by the US Food and Drug Administration
- Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
This page contains brief information about nadofaragene firadenovec-vncg and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials
- Package Insert - ADSTILADRIN
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
|
|
|